<p>Taysha Gene Therapies（納斯達克代碼：TSHA - 獲取免費報告）預計將在 2026 年 5 月 6 日星期三市場開盤前發佈其 2026 年第一季度財報。分析師預計 Taysha Gene Therapies 將發佈每股收益（$0.10）和季度收入為 75.60 萬美元。感興趣的人員被鼓勵訪問公司即將發佈的 2026 年第一季度財報概覽頁面，以獲取關於定於 2026 年 5 月 6 日東部時間上午 8:30 的電話會議的最新詳情。</p>
<ul>
<li>Neurogene 股票暴跌 44%：這家生物技術公司還有希望嗎？</li>
</ul>
<p>Taysha Gene Therapies（納斯達克代碼：TSHA - 獲取免費報告）上一次發佈季度財報是在 3 月 19 日星期四。該公司報告的季度每股收益為（$0.08），超出分析師的共識預期（$0.11）$0.03。該公司的季度收入為 549 萬美元，而共識預期為 189 萬美元。分析師平均預計 Taysha Gene Therapies 在當前財年和下一個財年將發佈每股收益為$0。</p>
<p>獲取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
<h2>Taysha Gene Therapies 股票下跌 0.9%</h2>
<p>TSHA 在星期五開盤價為$6.33。該公司的債務與股本比率為 0.20，流動比率為 12.23，速動比率為 12.23。公司的 50 日移動平均線為$4.95，200 日移動平均線為$4.89。Taysha Gene Therapies 的 52 周低點為$1.85，52 周高點為$6.76。該公司的市值為 18.2 億美元，市盈率為-18.62，貝塔值為 1.25。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>3 只小盤股適合你的秋季購物清單</li>
</ul>
<p>多家研究公司最近對 TSHA 進行了評估。華爾街 Zen 在 3 月 21 日星期六的研究報告中將 Taysha Gene Therapies 的評級從 “賣出” 上調至 “持有”。Needham &amp; Company LLC 在 3 月 19 日星期四的研究報告中將 Taysha Gene Therapies 的目標價從$10.00 上調至$12.00，並給予該公司 “買入” 評級。Chardan Capital 在 3 月 19 日星期四的研究報告中重申了 “買入” 評級，並設定了$12.00 的目標價。Weiss Ratings 在 3 月 27 日星期五的研究報告中重申了對 Taysha Gene Therapies 的 “賣出（d-）” 評級。最後，Truist Financial 在 3 月 25 日星期三的研究報告中將 Taysha Gene Therapies 的評級上調至 “強力買入”。兩位投資分析師給予該股票 “強力買入” 評級，十位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為$11.64。</p>
<p><strong>閲讀我們關於 Taysha Gene Therapies 的最新股票分析</strong></p>
<h2>內部買賣情況</h2>
<p>在其他 Taysha Gene Therapies 的新聞中，內部人士 Sukumar Nagendran 在 4 月 10 日星期五出售了 200,000 股 Taysha Gene Therapies 的股票。股票以平均價格$4.46 出售，總價值為$892,000.00。出售後，該內部人士持有公司 1,136,410 股股票，價值約為$5,068,388.60。此次交易使其持股減少了 14.97%。該交易已在與 SEC 的法律文件中披露，可以通過此鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。公司內部人士持有公司股票的 3.78%。</p>
<h2>Taysha Gene Therapies 的機構交易</h2>
<p>對該股票的對沖基金最近增加或減少了其持股。Marex Group plc 在第二季度購買了 Taysha Gene Therapies 的新股份，價值約$29,000。E Fund Management Co. Ltd.在第二季度購買了 Taysha Gene Therapies 的新股份，價值約$31,000。Tower Research Capital LLC TRC 在第二季度將其在 Taysha Gene Therapies 的持股增加了 156.5%。Tower Research Capital LLC TRC 現在擁有 17,606 股公司股票，價值$41,000，此前在此期間又購買了 10,742 股。BNP Paribas Financial Markets 在第二季度將其在 Taysha Gene Therapies 的持股增加了 51.9%。BNP Paribas Financial Markets 現在擁有 18,591 股公司股票，價值$43,000，此前在此期間又購買了 6,350 股。最後，Caitong International Asset Management Co. Ltd 在第四季度將其在 Taysha Gene Therapies 的持股增加了 143.8%。Caitong International Asset Management Co. Ltd 現在擁有 7,811 股公司股票，價值$43,000，此前在此期間又購買了 4,607 股。機構投資者持有公司 77.70% 的股票。</p>
<h2>Taysha Gene Therapies 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Taysha Gene Therapies, Inc（納斯達克：TSHA）是一家臨牀階段的生物技術公司，專注於開發針對中樞神經系統罕見單基因疾病的基因療法。該公司使用專有的腺病毒相關病毒（AAV）載體平台，設計新型衣殼和調控元件，以優化治療基因的遞送和表達。其產品管線包括針對 GM2 神經節苷脂症（Tay-Sachs 和 Sandhoff 病）的 TSHA-102，針對 GM1 神經節苷脂症的 TSHA-101，以及針對芳香 L-氨基酸脱羧酶（AADC）缺乏症的 TSHA-103，以及針對其他危及生命的兒科中樞神經系統疾病的早期候選藥物。</p>
<p>Taysha Gene Therapies 成立於 2019 年，總部位於德克薩斯州達拉斯，於 2021 年 5 月完成首次公開募股。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Taysha Gene Therapies</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Taysha Gene Therapies 嗎？</h2>
<p>在你考慮 Taysha Gene Therapies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Taysha Gene Therapies 並不在名單上。</p>
<p>雖然 Taysha Gene Therapies 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TSHA

動態生物技術與基因組 ETF - Invesco

基因改革 ETF - ARK

<p>Taysha Gene Therapies（納斯達克代碼：TSHA）將於 5 月 6 日發佈 2026 年第一季度財報，分析師預測每股虧損 0.10 美元，收入為 75.6 萬美元。該公司此前報告了 2025 年第一季度每股虧損 0.08 美元，超出預期。TSHA 的股票目前下跌 0.9%，市值為 18.2 億美元。最近的分析師評級包括買入和持有的混合推薦，平均目標價為 11.64 美元。內部交易活動顯示一位高管進行了大額出售，而機構持股比例為 77.70%</p>

<p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Taysha Gene Therapies to post earnings of ($0.10) per share and revenue of $0.7560 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（納斯達克代碼：TSHA - 獲取免費報告）預計將在 2026 年 5 月 6 日星期三市場開盤前發佈其 2026 年第一季度財報。分析師預計 Taysha Gene Therapies 將發佈每股收益（$0.10）和季度收入為 75.60 萬美元。感興趣的人員被鼓勵訪問公司即將發佈的 2026 年第一季度財報概覽頁面，以獲取關於定於 2026 年 5 月 6 日東部時間上午 8:30 的電話會議的最新詳情。</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：這家生物技術公司還有希望嗎？</li>
</ul>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（納斯達克代碼：TSHA - 獲取免費報告）上一次發佈季度財報是在 3 月 19 日星期四。該公司報告的季度每股收益為（$0.08），超出分析師的共識預期（$0.11）$0.03。該公司的季度收入為 549 萬美元，而共識預期為 189 萬美元。分析師平均預計 Taysha Gene Therapies 在當前財年和下一個財年將發佈每股收益為$0。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
</div><h2>Taysha Gene Therapies Stock Down 0.9%</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 股票下跌 0.9%</h2>
</div><p>TSHA opened at $6.33 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. The company's 50-day moving average is $4.95 and its 200 day moving average is $4.89. Taysha Gene Therapies has a fifty-two week low of $1.85 and a fifty-two week high of $6.76. The firm has a market capitalization of $1.82 billion, a P/E ratio of -18.62 and a beta of 1.25.</p>
<div class="lb-trans"><p>TSHA 在星期五開盤價為$6.33。該公司的債務與股本比率為 0.20，流動比率為 12.23，速動比率為 12.23。公司的 50 日移動平均線為$4.95，200 日移動平均線為$4.89。Taysha Gene Therapies 的 52 周低點為$1.85，52 周高點為$6.76。該公司的市值為 18.2 億美元，市盈率為-18.62，貝塔值為 1.25。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盤股適合你的秋季購物清單</li>
</ul>
</div><p>A number of research firms recently weighed in on TSHA. Wall Street Zen raised shares of Taysha Gene Therapies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, March 21st. Needham &amp; Company LLC raised their price target on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 19th. Chardan Capital reissued a &#34;buy&#34; rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Finally, Truist Financial raised shares of Taysha Gene Therapies to a &#34;strong-buy&#34; rating in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average target price of $11.64.</p>
<div class="lb-trans"><p>多家研究公司最近對 TSHA 進行了評估。華爾街 Zen 在 3 月 21 日星期六的研究報告中將 Taysha Gene Therapies 的評級從 “賣出” 上調至 “持有”。Needham &amp; Company LLC 在 3 月 19 日星期四的研究報告中將 Taysha Gene Therapies 的目標價從$10.00 上調至$12.00，並給予該公司 “買入” 評級。Chardan Capital 在 3 月 19 日星期四的研究報告中重申了 “買入” 評級，並設定了$12.00 的目標價。Weiss Ratings 在 3 月 27 日星期五的研究報告中重申了對 Taysha Gene Therapies 的 “賣出（d-）” 評級。最後，Truist Financial 在 3 月 25 日星期三的研究報告中將 Taysha Gene Therapies 的評級上調至 “強力買入”。兩位投資分析師給予該股票 “強力買入” 評級，十位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為$11.64。</p>
</div><p><strong>Read Our Latest Stock Analysis on Taysha Gene Therapies</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Taysha Gene Therapies 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><p>In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider owned 1,136,410 shares of the company's stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Taysha Gene Therapies 的新聞中，內部人士 Sukumar Nagendran 在 4 月 10 日星期五出售了 200,000 股 Taysha Gene Therapies 的股票。股票以平均價格$4.46 出售，總價值為$892,000.00。出售後，該內部人士持有公司 1,136,410 股股票，價值約為$5,068,388.60。此次交易使其持股減少了 14.97%。該交易已在與 SEC 的法律文件中披露，可以通過此鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。公司內部人士持有公司股票的 3.78%。</p>
</div><h2>Institutional Trading of Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的機構交易</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc bought a new stake in Taysha Gene Therapies in the second quarter worth about $29,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the second quarter worth about $31,000. Tower Research Capital LLC TRC raised its position in Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock worth $41,000 after acquiring an additional 10,742 shares during the period. BNP Paribas Financial Markets raised its position in Taysha Gene Therapies by 51.9% in the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company's stock worth $43,000 after acquiring an additional 6,350 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its position in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock worth $43,000 after acquiring an additional 4,607 shares during the period. Institutional investors own 77.70% of the company's stock.</p>
<div class="lb-trans"><p>對該股票的對沖基金最近增加或減少了其持股。Marex Group plc 在第二季度購買了 Taysha Gene Therapies 的新股份，價值約$29,000。E Fund Management Co. Ltd.在第二季度購買了 Taysha Gene Therapies 的新股份，價值約$31,000。Tower Research Capital LLC TRC 在第二季度將其在 Taysha Gene Therapies 的持股增加了 156.5%。Tower Research Capital LLC TRC 現在擁有 17,606 股公司股票，價值$41,000，此前在此期間又購買了 10,742 股。BNP Paribas Financial Markets 在第二季度將其在 Taysha Gene Therapies 的持股增加了 51.9%。BNP Paribas Financial Markets 現在擁有 18,591 股公司股票，價值$43,000，此前在此期間又購買了 6,350 股。最後，Caitong International Asset Management Co. Ltd 在第四季度將其在 Taysha Gene Therapies 的持股增加了 143.8%。Caitong International Asset Management Co. Ltd 現在擁有 7,811 股公司股票，價值$43,000，此前在此期間又購買了 4,607 股。機構投資者持有公司 77.70% 的股票。</p>
</div><h2>Taysha Gene Therapies Company Profile</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc（納斯達克：TSHA）是一家臨牀階段的生物技術公司，專注於開發針對中樞神經系統罕見單基因疾病的基因療法。該公司使用專有的腺病毒相關病毒（AAV）載體平台，設計新型衣殼和調控元件，以優化治療基因的遞送和表達。其產品管線包括針對 GM2 神經節苷脂症（Tay-Sachs 和 Sandhoff 病）的 TSHA-102，針對 GM1 神經節苷脂症的 TSHA-101，以及針對芳香 L-氨基酸脱羧酶（AADC）缺乏症的 TSHA-103，以及針對其他危及生命的兒科中樞神經系統疾病的早期候選藥物。</p>
</div><p>Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 成立於 2019 年，總部位於德克薩斯州達拉斯，於 2021 年 5 月完成首次公開募股。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Taysha Gene Therapies</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Taysha Gene Therapies 嗎？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Taysha Gene Therapies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Taysha Gene Therapies 並不在名單上。</p>
</div><p>While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Taysha Gene Therapies 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Taysha Gene Therapies (TSHA) 將在週三公佈其財務業績